The estimated Net Worth of Matthew Ronsheim is at least $113 Tisíc dollars as of 19 October 2021. Dr Ronsheim owns over 3,759 units of Entasis Therapeutics Inc stock worth over $101,268 and over the last 4 years he sold ETTX stock worth over $11,991.
Dr has made over 1 trades of the Entasis Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,759 units of ETTX stock worth $11,991 on 19 October 2021.
The largest trade he's ever made was selling 3,759 units of Entasis Therapeutics Inc stock on 19 October 2021 worth over $11,991. On average, Dr trades about 376 units every 0 days since 2021. As of 19 October 2021 he still owns at least 46,241 units of Entasis Therapeutics Inc stock.
You can see the complete history of Dr Ronsheim stock trades at the bottom of the page.
Dr. Matthew Ronsheim Ph.D. is the Chief Pharmaceutical Sciences & Manufacturing Officer at Entasis Therapeutics Inc.
Dr D is 49, he's been the Chief Pharmaceutical Sciences & Manufacturing Officer of Entasis Therapeutics Inc since . There are 7 older and no younger executives at Entasis Therapeutics Inc. The oldest executive at Entasis Therapeutics Holdings Inc is Dr. John Patrick Mueller Ph.D., 61, who is the Chief Devel. Officer.
Matthew's mailing address filed with the SEC is 35 GATEHOUSE DRIVE, , WALTHAM, MA, 02451.
Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo... a Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
Entasis Therapeutics Inc executives and other stock owners filed with the SEC include: